A civic hospital’s medicine supply chain just became a crime scene, and the two agencies meant to protect patients are accusing each other of failing them.
The Maharashtra Food and Drug Administration seized medicines valued at ₹1.72 crore from the Central Drug Store at Yashwantrao Chavan Memorial Hospital in Pimpri-Chinchwad on November 4, calling it a raid prompted by quality failures and missing manufacturing licenses.
The Pimpri-Chinchwad Municipal Corporation (PCMC) says it wasn’t a raid at all — that civic officials had already pulled the stock months earlier, blacklisted the supplier, and simply handed over the quarantined bottles when FDA inspectors arrived, The Indian Express reported.
The dispute leaves a gap in accountability. If the civic body caught the problem in February, why did the regulator need five months to confirm it? And if the FDA seized ₹1.72 crore worth of drugs, why does the hospital say the stock was worth barely ₹11.95 lakh? “while FDA has delayed its action by five months.” PCMC said
“It was not a raid by FDA. In fact, in February this year, after a patient complaint to us that a particular medicine was proving ineffective for an ailment, we had suo motu approached the FDA.”
Kuldeep Jangam, Additional Municipal Commissioner, PCMC, told The Indian Express.
The complaint that started it
The trail begins on February 14, when Thergaon Hospital, a PCMC facility, flagged that capsules of B-Complex with Zinc (brand name CareZinc) appeared ineffective. Nine days later, PCMC wrote to the FDA requesting testing and took the stock out of circulation. FDA inspectors collected samples the same day, February 23.

The manufacturer was Inducare Pharmaceuticals and Research Foundation, based in Jejuri MIDC, Pune. The supplier was M/s Vinayak Pharma, Pune. The FDA’s laboratory report landed on July 16 — nearly five months later — confirming the medicine was not of standard quality.
By then, PCMC had already acted. The civic body blacklisted Inducare for three years and restricted Vinayak Pharma for the same period. No payment had been made to the supplier for the contested batch, Jangam said.
What the FDA found
The regulator tells a different story. FDA Joint Commissioner Girish Hukare insisted the November 4 action was a raid, conducted as follow-up after the July report. During document checks at the Jejuri unit, officials discovered the manufacturer lacked valid permissions for several of the medicines supplied to YCM Hospital. A show-cause notice went out on October 29.
Drug Inspector S.S. Bugad collected samples from the hospital’s central store. Lab analysis reportedly identified deficiencies in assay, dissolution, description, uniformity of weight, and labelling across multiple samples, Pune Mirror reported.
To prevent further distribution, the FDA seized 10 categories of medicines from the hospital under the Drugs and Cosmetics Act, 1940. It also seized medicines worth around ₹17.58 lakh from the Jejuri manufacturing unit itself.
Two valuations, one stock
The valuation gap is stark. The FDA estimates the hospital stock at ₹1.72 crore. PCMC says the 11 medicine types seized were worth ₹11.95 lakh at tender value. DrugsControl Media Services corroborated the FDA’s ₹1.73 crore figure in its own report.
PCMC argues the higher number inflates the scale of the seizure by counting medicines already quarantined and valueless to the civic body. The FDA’s figure suggests a far larger volume of suspect drugs may have been sitting in the supply chain.
The delay that matters
Hukare attributed the five-month testing lag to volume: the lab receives samples from across the state. He said the FDA had immediately asked PCMC to keep the complained-of medicine aside.
But the timeline raises a harder question. If the regulator told the hospital to quarantine the stock in February, and the hospital says it did, what changed between July and November? The FDA’s raid seized drugs PCMC claims were already segregated.
If the system worked — complaint, quarantine, test, blacklist — the November action looks like theater. If it didn’t, patients may have been exposed to medicines that failed assay, dissolution, and weight uniformity tests for months.
“We had indeed conducted a raid as a follow up measure after we found that the medicines given for testing were not upto the required standards.”
Hukare told The Indian Express.
What happens next
The FDA said it will file court cases against the manufacturers for producing and supplying poor-quality medicine without valid permissions. PCMC maintains its prior action — blacklisting, non-payment, quarantine — was sufficient and timely.
Dr Laxman Gophane, PCMC’s health medical officer, reiterated Saturday that no raid occurred and the civic body’s initiative prioritized patient safety. The regulator and the corporation now stand on opposite sides of the same seizure, each claiming the other moved too slowly.
The next court filing will test whose version holds.